Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;5(2):R30-6.
doi: 10.1186/bcr568. Epub 2003 Jan 13.

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Claus M Schlotter  1 , Ulf Vogt, Ulrich Bosse, Berthold Mersch, Katja Wassmann
Affiliations

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Claus M Schlotter et al. Breast Cancer Res. 2003.

Abstract

Background: At present, node-negative, high-risk breast cancer patients cannot be identified with sufficient accuracy. Consequently, further strong prognostic factors are needed.

Methods: Among 181 node-negative breast cancer (NNBC) patients, c-myc and HER-2/neu oncogenes were identified prospectively using double differential PCR. The possible impact of amplification of those oncogenes on disease-free survival (DFS) and overall survival was examined. Furthermore, the possible effects of adjuvant therapies on rate of recurrence and mortality in oncogene-amplified NNBC patients were investigated.

Results: The prevalence rates for amplification of c-myc and HER-2/neu were 21.5% and 30.4%, respectively. On univariate analysis, c-myc-amplified NNBCs were associated with significantly shorter DFS at 36 months after the initial diagnosis (85.3% versus 97.3%). As compared with nonamplified cancers, HER-2/neu-amplified NNBCs did not exhibit any significant differences after 36 months and 95 months. Multivariate analysis indicated that c-myc amplification and tumour size, in contrast to HER-2/neu amplification, oestrogen receptor status, grading and age, were the only independent parameters for DFS. During the period of observation, we found no evidence for an impact of amplification of the oncogenes on overall survival in all cases. With respect to various adjuvant systemic therapies such as chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil; fluorouracil, epirubicin, cyclophosphamide) and endocrine therapy (tamoxifen), no significant differences were identified in oncogene-amplified NNBC patients in terms of DFS and overall survival. However, those c-myc-amplified NNBC patients who did not receive adjuvant systemic therapy exhibited significantly shorter DFS and overall survival as compared with c-myc-nonamplified patients.

Conclusion: C-myc amplification appears to be a strong prognostic marker with which to predict early recurrence in NNBC patients. C-myc-amplified NNBC patients without adjuvant systemic therapy experienced shorter DFS and overall survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification and Regression Trees (CART) analysis of c-myc among 181 node-negative breast cancer patients. dd, double differential.
Figure 2
Figure 2
Kaplan–Meier estimation of disease-free survival (DFS) among 181 node-negative breast cancer patients.
See this image and copyright information in PMC

Comment in

References

    1. McGuire W. Adjuvant therapy of node-negative breast cancer. N Engl J Med. 1989;320:525–527. - PubMed
    1. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–489. - PubMed
    1. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerman DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer. N Engl J Med. 1989;320:473–478. - PubMed
    1. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire W. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599–605. - PubMed
    1. Nicholson S, Wright S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Farndon JR, Harns AL. Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem. 1990;27:811–815. - PubMed